Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.20
-$0.06(-3.70%)
At close: 4:00 PM EST
$0.20
-$0.06(-3.70%)
Day’s Range― - ―
52-Week Range$0.16 - $0.86
Previous CloseN/A
Volume37.66K
Average Volume (3M)8.88M
Market Cap
$11.52M
Enterprise Value-$1.10M
Total Cash (Recent Filing)$14.43M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-3.67
Enterprise Value/Gross Profit-3.99
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$2.50Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
Regulatory Path ClarityRegulatory alignment to support a pivotal Phase 3 materially reduces program execution risk and clarifies the path to potential approval. Over months this fosters focused resource allocation, improves trial design predictability, and increases the appeal to strategic partners or non-dilutive funders.
Published Clinical And Translational DataPeer-reviewed Phase 1 results demonstrating stroma degradation (PH20), sustained viral presence, and increased tumor T‑cell infiltration provide durable scientific validation of VCN‑01's mechanism. This strengthens differentiation, informs optimal combination strategies, and supports regulatory and collaborator confidence long term.
Low Financial LeverageLow reported debt relative to equity preserves balance sheet flexibility and limits fixed financing obligations. Structurally, this reduces refinancing pressure, giving management optionality to pursue partnerships, licensing, or equity raises without immediate heavy interest burdens.
Bears Say
Sustained Cash BurnConsistent negative operating and free cash flow of roughly -$14.4M TTM indicates ongoing funding needs. Over a multi-month horizon this necessitates recurrent capital raises or deals, raising dilution and execution risk and potentially forcing timeline compression or program prioritization if financing is delayed.
Deep, Persistent Losses And Minimal RevenueVery low revenue and large recurring operating losses show the company remains pre-commercial and heavily investment‑driven. Over months this limits internal funding capacity, depresses return metrics, and prolongs dependency on external capital, constraining long-term strategic flexibility.
Warrant Vote And Financing UncertaintyRepeated inability to obtain a quorum for warrant-related votes creates procedural timing risk around planned equity issuance. This recurring governance hurdle can delay expected cash inflows, complicate investor relations, and increase uncertainty around the company’s near-term financing runway.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $0.86 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $11.52M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Aug 12, 2026 which is in 36 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on May 05, 2026. The company reported -$0.05 earnings per share for the quarter, the consensus estimate of -$0.05 by $0.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.06.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.05 in its last earnings report, expectations of -$0.05. Following the earnings report the stock price went up 0.526%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$2.50
▲(1150.00% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.90% Mutual Funds
0.33% Other Institutional Investors
97.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---